JP6474420B2 - 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現 - Google Patents

組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現 Download PDF

Info

Publication number
JP6474420B2
JP6474420B2 JP2016549077A JP2016549077A JP6474420B2 JP 6474420 B2 JP6474420 B2 JP 6474420B2 JP 2016549077 A JP2016549077 A JP 2016549077A JP 2016549077 A JP2016549077 A JP 2016549077A JP 6474420 B2 JP6474420 B2 JP 6474420B2
Authority
JP
Japan
Prior art keywords
cell
culture
protein
cells
recombinant protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505620A (ja
JP2017505620A5 (cg-RX-API-DMAC7.html
Inventor
グプタ，シバーニ
カン，ソヘ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53757626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6474420(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2017505620A publication Critical patent/JP2017505620A/ja
Publication of JP2017505620A5 publication Critical patent/JP2017505620A5/ja
Application granted granted Critical
Publication of JP6474420B2 publication Critical patent/JP6474420B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01101—Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.101)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01143—Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.143)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01094—Protein N-acetylglucosaminyltransferase (2.4.1.94)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2016549077A 2014-01-29 2014-12-11 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現 Active JP6474420B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933137P 2014-01-29 2014-01-29
US61/933,137 2014-01-29
PCT/US2014/069744 WO2015116315A1 (en) 2014-01-29 2014-12-11 Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019011871A Division JP6797950B2 (ja) 2014-01-29 2019-01-28 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現

Publications (3)

Publication Number Publication Date
JP2017505620A JP2017505620A (ja) 2017-02-23
JP2017505620A5 JP2017505620A5 (cg-RX-API-DMAC7.html) 2017-11-30
JP6474420B2 true JP6474420B2 (ja) 2019-02-27

Family

ID=53757626

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549077A Active JP6474420B2 (ja) 2014-01-29 2014-12-11 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現
JP2019011871A Active JP6797950B2 (ja) 2014-01-29 2019-01-28 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現
JP2020190707A Active JP7034236B2 (ja) 2014-01-29 2020-11-17 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
JP2022029077A Active JP7788307B2 (ja) 2014-01-29 2022-02-28 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019011871A Active JP6797950B2 (ja) 2014-01-29 2019-01-28 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現
JP2020190707A Active JP7034236B2 (ja) 2014-01-29 2020-11-17 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
JP2022029077A Active JP7788307B2 (ja) 2014-01-29 2022-02-28 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現

Country Status (14)

Country Link
US (3) US10227627B2 (cg-RX-API-DMAC7.html)
EP (1) EP3099806A1 (cg-RX-API-DMAC7.html)
JP (4) JP6474420B2 (cg-RX-API-DMAC7.html)
KR (3) KR102410393B1 (cg-RX-API-DMAC7.html)
CN (2) CN106170554B (cg-RX-API-DMAC7.html)
AU (3) AU2014380174C1 (cg-RX-API-DMAC7.html)
BR (1) BR112016017606A2 (cg-RX-API-DMAC7.html)
CA (1) CA2938079C (cg-RX-API-DMAC7.html)
CL (1) CL2016001900A1 (cg-RX-API-DMAC7.html)
EA (2) EA037565B1 (cg-RX-API-DMAC7.html)
IL (3) IL282517B (cg-RX-API-DMAC7.html)
MX (2) MX377780B (cg-RX-API-DMAC7.html)
SG (1) SG10201912081RA (cg-RX-API-DMAC7.html)
WO (1) WO2015116315A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
EP3596225A1 (en) * 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
KR102648479B1 (ko) * 2019-06-10 2024-03-15 초 플러스 인크. 단백질 기반 의약들 (protein-based pharmaceuticals) 의 고 수준 생산을 위한 세포주들 (cell lines)
BR112023021867A2 (pt) 2021-04-23 2023-12-19 Amgen Inc Composições de anticorpo anti-tslp e seus usos
TW202309087A (zh) * 2021-05-03 2023-03-01 德商百靈佳殷格翰國際股份有限公司 製備spesolimab之方法
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1720972B1 (en) 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
WO2008154014A2 (en) * 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
KR20110139292A (ko) * 2009-04-20 2011-12-28 화이자 인코포레이티드 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
WO2011109600A1 (en) * 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
CA2794697A1 (en) * 2010-04-07 2011-10-13 Momenta Pharmaceuticals, Inc. High mannose glycans
TW201209160A (en) * 2010-04-27 2012-03-01 Lonza Ag Improved glycosylation of proteins in host cells
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
BR112014016614B1 (pt) 2012-01-11 2022-02-01 Sigma-Aldrich Co. Llc Métodos para produzir uma célula deficiente em manosil (alfa-1,3-)-glicoproteína beta-1,2- nacetilglucosa-miniltransferase i (mgat1) e produzir uma proteína recombinante apresentando um ou mais resíduos de manose terminal

Also Published As

Publication number Publication date
AU2014380174A1 (en) 2016-08-11
AU2018264100A1 (en) 2018-12-06
JP2017505620A (ja) 2017-02-23
BR112016017606A2 (pt) 2017-10-10
JP7788307B2 (ja) 2025-12-18
EA037565B1 (ru) 2021-04-14
US10655156B2 (en) 2020-05-19
CA2938079C (en) 2022-10-11
JP2022068365A (ja) 2022-05-09
MX377780B (es) 2025-03-11
CN106170554B (zh) 2021-08-17
SG10201912081RA (en) 2020-02-27
US20200277642A1 (en) 2020-09-03
KR20160111943A (ko) 2016-09-27
KR102301034B1 (ko) 2021-09-13
IL246914A0 (en) 2016-09-29
IL270861B (en) 2021-05-31
IL282517B (en) 2022-07-01
KR20220086703A (ko) 2022-06-23
CN106170554A (zh) 2016-11-30
IL270861A (en) 2020-01-30
MX2020012356A (es) 2021-01-29
US20190153496A1 (en) 2019-05-23
AU2018264100C1 (en) 2025-06-05
AU2020239681C1 (en) 2025-06-05
WO2015116315A1 (en) 2015-08-06
JP2021040638A (ja) 2021-03-18
CN113774084B (zh) 2024-04-16
AU2018264100B2 (en) 2020-07-23
EP3099806A1 (en) 2016-12-07
AU2014380174C1 (en) 2025-06-05
CN113774084A (zh) 2021-12-10
JP6797950B2 (ja) 2020-12-09
AU2020239681A1 (en) 2020-10-15
IL282517A (en) 2021-06-30
CA2938079A1 (en) 2015-08-06
EA202190244A3 (ru) 2021-08-31
US20190010532A1 (en) 2019-01-10
KR102519540B1 (ko) 2023-04-10
US10907186B2 (en) 2021-02-02
MX2016009911A (es) 2016-10-28
JP2019088305A (ja) 2019-06-13
EA201691532A1 (ru) 2017-01-30
IL246914B (en) 2019-12-31
AU2020239681B2 (en) 2022-06-23
CL2016001900A1 (es) 2017-05-12
EA202190244A2 (ru) 2021-05-31
AU2014380174B2 (en) 2018-08-30
KR102410393B1 (ko) 2022-06-16
JP7034236B2 (ja) 2022-03-11
US10227627B2 (en) 2019-03-12
KR20210114549A (ko) 2021-09-23

Similar Documents

Publication Publication Date Title
JP7788307B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
AU2018201844C1 (en) Use Of Monensin To Regulate Glycosylation Of Recombinant Proteins
US10106829B2 (en) Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
HK1231928A1 (en) Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
HK1231928B (zh) 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
EA047078B1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190129

R150 Certificate of patent or registration of utility model

Ref document number: 6474420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250